- Report
- December 2023
- 80 Pages
China
From €1432EUR$1,500USD£1,199GBP
- Report
- December 2023
- 80 Pages
France
From €1432EUR$1,500USD£1,199GBP
- Report
- December 2023
- 80 Pages
Germany
From €1432EUR$1,500USD£1,199GBP
- Report
- December 2023
- 80 Pages
India
From €1432EUR$1,500USD£1,199GBP
- Report
- December 2023
- 80 Pages
Ireland
From €1432EUR$1,500USD£1,199GBP
- Report
- December 2023
- 80 Pages
Japan
From €1432EUR$1,500USD£1,199GBP
- Report
- December 2023
- 80 Pages
Russia
From €1432EUR$1,500USD£1,199GBP
- Report
- December 2023
- 80 Pages
Saudi Arabia
From €1432EUR$1,500USD£1,199GBP
- Report
- December 2023
- 80 Pages
South Korea
From €1432EUR$1,500USD£1,199GBP
- Report
- December 2023
- 80 Pages
United States
From €1432EUR$1,500USD£1,199GBP
- Report
- December 2023
- 80 Pages
Vietnam
From €1432EUR$1,500USD£1,199GBP
- Report
- December 2023
- 180 Pages
Global
From €2386EUR$2,500USD£1,999GBP
- Report
- January 2022
- 182 Pages
Global
From €3436EUR$3,600USD£2,879GBP
- Report
- November 2023
- 93 Pages
Global
From €3500EUR$3,929USD£3,035GBP
- Report
- March 2025
- 87 Pages
Global
From €3500EUR$3,929USD£3,035GBP
- Report
- January 2025
- 132 Pages
Global
From €907EUR$950USD£760GBP
- Report
- November 2021
- 527 Pages
Global
From €3818EUR$4,000USD£3,199GBP
- Report
- July 2024
- 280 Pages
Global
From €2534EUR$2,655USD£2,123GBP
- Report
- July 2022
- 234 Pages
Global
From €3407EUR$3,570USD£2,855GBP

RNAi therapy is a type of biotechnology that uses small pieces of RNA to target and silence specific genes. This technology has been used to treat a variety of diseases, including cancer, cardiovascular disease, and neurological disorders. RNAi therapy works by introducing small interfering RNAs (siRNAs) into cells, which then bind to and degrade messenger RNAs (mRNAs) that encode for specific proteins. This process can be used to reduce the expression of disease-causing genes, or to activate beneficial genes.
RNAi therapy has the potential to revolutionize the treatment of many diseases, as it is a more precise and targeted approach than traditional drug therapies. It is also less toxic and has fewer side effects. However, the development of RNAi therapies is still in its early stages, and there are many challenges that need to be addressed before they can be widely used in clinical settings.
Some companies in the RNAi therapy market include Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, and Moderna Therapeutics. Show Less Read more